darapladib

a selective lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) inhibitor, on biomarkers of cardiovascular (CV) risk

Also Known As:

N- (2- (diethylamino)ethyl)- 2- (2- ((4- fluorobenzyl)sulfanyl)- 4- oxo- 4,5,6,7- tetrahydro- 1H- cyclopentapyrimidin- 1- yl)- N- ((4'- (trifluoromethyl)biphenyl- 4- yl)methyl)acetamide; SB-480848

Pharmalogical Action Categories:

D064801 - Phospholipase A2 Inhibitors

Organic Chemicals: 140
- Amines: 4925
  - Ethylamines: 5
    - Diethylamines
      - darapladib: 102
- Hydrocarbons: 1726
  - Cyclic Hydrocarbons: 96
    - Aromatic Hydrocarbons: 295
      - Benzene Derivatives: 17
        Biphenyl Compounds: 7
        darapladib: 102
- Sulfur Compounds: 283
  - Sulfides: 1092
    - darapladib: 102
Heterocyclic Compounds: 207
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 521
    - Pyrimidinones: 74
      - darapladib: 102
Inorganic Chemicals: 9
- Electrolytes: 16464
  - Ions: 8156
    - Anions: 3558
      - Sulfides: 1092
        darapladib: 102
- Sulfur Compounds: 283
  - Hydrogen Sulfide: 2855
    - Sulfides: 1092
      - darapladib: 102

John M Gregson Selected Research

John M Gregson Research Topics

Disease

Drug/Important Bio-Agent (IBA)